Skip to main content
NVCR
NASDAQ Life Sciences

NovoCure's Glioblastoma Trial Misses Primary Endpoint, Shares Down 11%

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$14.16
Mkt Cap
$2.067B
52W Low
$9.82
52W High
$18.92
52W Position info
44% above low
Off High info
25% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NVCR sits 44% above its 52-week low of $9.82.

Summary

NovoCure's Phase 3 TRIDENT trial for glioblastoma failed to meet its primary endpoint, showing no statistically significant improvement in overall survival. Patients initiating treatment earlier had a median overall survival of 17.7 months, barely different from 17.5 months for later initiation. This follows an 8-K filed earlier today disclosing these results. Missing a late-stage trial endpoint for a key indication is a significant setback for the company's pipeline and future revenue potential, leading to an 11% drop in premarket trading.

At the time of this announcement, NVCR was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $9.82 to $18.92. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $10.94 info
Change: -$3.01 (-22%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $10.94 info
Change: -$3.31 (-23%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $10.94 info
Change: -$4.40 (-29%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $10.94 info
Change: -$3.31 (-23%) info
Market Cap: $1.279B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $10.94 info
Change: -$5.12 (-32%) info
Market Cap: $1.279B info